openevidence-com

Explore More CapabilitiesAmerica's Official Medical Knowledge PlatformAn Official AI Partner of The New England Journal of Medicine. OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine.An Official AI Partner of JAMA and the JAMA Network specialty journals. OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from JAMA and the JAMA Network specialty journals.An Official AI Partner of the National Comprehensive Cancer Network (NCCN). OpenEvidence content includes NCCN Guidelines® Treatment Algorithms, Flowcharts, and Pathways.An Official AI Partner of Cochrane Systematic Reviews. OpenEvidence content includes figures, tables, multimedia and full-text from Cochrane Systematic Reviews.Society PartnersPartnerships include NCCN, ACC, ADA, AAFP, AAOS, AAO-HNS, ACEP, GINA, SSO and moreGet OpenEvidence on iOS and AndroidOpenEvidence is FREE for verified U.S. HCPs.Supported by the BestInvestors include Sequoia, Google Ventures, Kleiner Perkins, Nvidia, Coatue, Thrive, Conviction, ICONIQ, Greycroft, Breyer Capital, BOND, Henry Kravis, Blackstone, DST, Mayo Clinic, and othersOpenEvidence is free and unlimited for healthcare professionals.Sign Up --- OpenEvidence is the leading medical information platform.An Official AI Partner of The New England Journal of Medicine. OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine.An Official AI Partner of JAMA and the JAMA Network specialty journals. OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from JAMA and the JAMA Network specialty journals.An Official AI Partner of the National Comprehensive Cancer Network (NCCN). OpenEvidence content includes NCCN Guidelines® Treatment Algorithms, Flowcharts, and Pathways.An Official AI Partner of Cochrane Systematic Reviews. OpenEvidence content includes figures, tables, multimedia and full-text from Cochrane Systematic Reviews.Our mission is to help doctors save lives and improve patient care.This year, more than 100 million Americans will be treated by a clinician using OpenEvidence.As a product, OpenEvidence is an AI copilot for doctors that helps them make high-stakes decisions at the point of care. OpenEvidence is the most widely used medical AI among verified U.S. physicians. To date, we have supported over 100 million AI-powered clinical consultations from U.S. doctors and other frontline clinicians.In a remarkably short period of time, OpenEvidence has become the default operating system of medical knowledge in the United States.TeamDaniel NadlerPhD, HarvardTIME100 Most Influential People in HealthZachary ZieglerPhD Candidate, HarvardWorked with Alexander RushJonas WulffPost-Doc, MITPhD, MPI for Intelligent SystemsWorked with Antonio TorralbaMicah SmithPhD, MITWorked with Kalyan VeeramachaneniEvan HernandezPhD, MITWorked with Jacob AndreasEric LehmanPhD, MITWorked with Peter SzolovitsLei XuPhD, MITWorked with Kalyan VeeramachaneniFernanda FerreiraPhD, HarvardJames EsdailePhD, HarvardFormerly @ Kensho TechnologiesAndy YoonBS, Computer Science, UCLAEthan JosephMEng, Computer Science, Cornell TechJagath Jai KumarMS, Computer Science, UMass AmherstFormerly @ GoogleOliver RenMEng, Computer Science, MITStephen PolcynBSE, Computer Science, PrincetonVarun MangalickBS, Computer Science and Mathematics, MITRobert McKenzieAB, Statistics, HarvardSam GilmanBA, Computer Science, WilliamsReese GreenBS, Computer Science and Mathematics, CU BoulderAakriti LakshmananMS, Computer Science, StanfordBenedict NeoMS, Data Science, USFKush KhoslaMS, Computer Science, StanfordFounder @ Amaro (Acquired by OpenEvidence)Sauren KhoslaMS, Computer Science, StanfordFounder @ Amaro (Acquired by OpenEvidence)Neel Patel-ShahBA, Cognitive Science, BerkeleyFormerly @ Amaro (Acquired by OpenEvidence)Dylan LyMS, Product Design, StanfordFormerly @ Amaro (Acquired by OpenEvidence)Marc LeefMEng, Computer Science, PrincetonBenjamin ChrobotBS, Computer Science and Engineering, MITAsha MaranBS, Computer Science and Cognitive Science, University of VirginiaMaya ShahBS, Computer Science and Business Administration, Carnegie Mellon UniversityChase BishopBS, Computer Science, Northeastern UniversityFormerly @ StripeVivien HoMBA, University of Pennsylvania, WhartonBS, Industrial Engineering, NorthwesternMondira RayMD, MBIBoston Children’s Hospital/Harvard Medical SchoolTina C. JeonBA, HSHM, Yale UniversityJD, Northwestern Pritzker School of LawJames PhimisterPhD, University of PennsylvaniaFormerly @ NEJM GroupTravis ZackMD, PhD, Harvard Medical School, MITAssistant Professor & AI Researcher, UCSFIf you think you would be a fit for this engineering team, tell us why at engineering@openevidence.com.Commercial TeamJeff EatonSachin NanavatiJack LindemanNick LumleyGreg LloydJack LaddBrett BaxterNick DiBiscegliaFrank DziobczynskiBilly SountornsornJessica KouryArianna MiskelKristen HornungAlex CalLaurent SchockmelDr. Ania BilskiKate EuckerMariah AoNour ZakiJacob LuskBegum DemirRick JohansonEllie LauderdaleSamuel RourkeCatherine FimianiMorgan CutlerMichael MillerNiall MacKenzieJac BrothersonStacey PearsonVika BoykoCollaboratorsIn Memoriam: Daniel Kahneman, PhDNobel Prize LaureateProfessor Emeritus, PrincetonAuthor of Thinking, Fast and SlowAlexander Rush, PhDComputer Science Faculty, CornellFormer Computer Science Faculty, HarvardPost-Doc, FAIR; Worked with Yann LeCunnPhD, MITMedical AdvisorsCedars-SinaiRam Dandillaya, MDClinical Chief, Department of CardiologyCardiologyMayo ClinicAntonio J. Forte, MD, PhDVice Chair for Research, Department of SurgeryPlastic SurgeryCleveland ClinicLeonard Calabrese, DOVice Chair, Rheumatic and Immunologic DiseasesRheumatologyGrady Memorial HealthSanjay Gupta, MDChief Medical Correspondent, CNNNeurosurgeryBoston Children’sJohn J. Lee, MDClinical Director, Food Allergy ProgramAllergy/ImmunologyUW MedicineSamuel Finlayson, MD, PhDMD, PhD, Harvard Medical SchoolGeneticsUW MedicineCindy Lin, MDMD, Harvard Medical SchoolPhysical Medicine and RehabilitationMGHAneesh Singhal, MDVice Chair, Department of NeurologyNeurologyUW MedicineMargaret Adam, MDEditor-in-Chief, GeneReviewsGeneticsUNCSpencer Dorn, MDVice Chair & Professor of MedicineGastroenterologySocial PresenceNisha Mehta, MDFounder of Physician Side GigsRadiologyJohns HopkinsVishal Patel, MDRheumatologyColumbiaMichael Sughrue, MD3000+ brain surgeries performedNeurosurgeryUMass Medical SchoolFrank Domino, MDFamily MedicineSocial PresenceWill Flanary, MDCreator of Dr. GlaucomfleckenOphthalmologyMGHAmbar Mehta, MDVascular SurgeryUCSFGeoffory Buckle, MDGI Oncology/Global HealthStanfordMarc Berg, MDCritical CareNYU LangoneNeil Shapiro, MDMedical EducationPrivate PracticeParesh Mane, MDCardiothoracic SurgeryAAO-HNSRahul Shah, MDCEO, American Academy of Otolaryngology–Head and Neck Surgery FoundationOtolaryngologyUCSFRyan Halvorson, MDOrthopedicsMGHSanskriti Varma, MDGastroenterologyNorthwesternJohn Bailitz, MDEmergency MedicineMGHDiane Somlo, MDHospital MedicineCity of HopeDivneet Mandair, MDOncologyUCSFKarthik Sarma, MDPsychiatryVALeila Mureebee, MDAI DirectorSurgeryMount SinaiEric Neibart, MDInfectious DiseaseSociety PartnersPartnerships include NCCN, ACC, ADA, AAFP, AAOS, AAO-HNS, ACEP, GINA, SSO and moreSupported by the BestInvestors include Sequoia, Google Ventures, Kleiner Perkins, Nvidia, Coatue, Thrive, Conviction, ICONIQ, Greycroft, Breyer Capital, BOND, Henry Kravis, Blackstone, DST, Mayo Clinic, and othersSecurity and ComplianceHIPAA compliant and SOC 2 Type II certified to protect your data. --- OpenEvidence and NEJM Group, publisher of the New England Journal of Medicine, sign content agreementClinicians using OpenEvidence benefit from content sourced from NEJM Group journalsFebruary 19, 2025CAMBRIDGE, MA, February 19, 2025 – OpenEvidence, the fastest-growing platform for doctors, has signed a multi-year content agreement with NEJM Group, publisher of the New England Journal of Medicine (NEJM). Under this agreement, all published content and multimedia from 1990 forward from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch will be provided to OpenEvidence to inform answers delivered on the OpenEvidence platform.“In serving clinicians, it is crucial that the trusted evidence we publish informs clinical decisions," said David Sampson, Vice President and Chief Publishing Officer of NEJM Group. “OpenEvidence is emerging as a preferred resource for many clinicians. We are delighted to support OpenEvidence as a content partner, and we look forward to further collaborating with OpenEvidence to improve the delivery of clinical knowledge.”“Information from trusted, expert sources is the foundation of evidence-based care, and faster answers to clinical questions through a medical search experience that is conversational, intuitive, delightful, and precise is the future of care,” said Daniel Nadler, Founder and CEO of OpenEvidence. “NEJM publishes the most trusted medical evidence in the world, and we are thrilled to establish this agreement in support of the clinicians we serve. Clinicians will benefit from answers derived from the latest invited reviews published in NEJM along with select figures, tables, and illustrations that are vital to helping doctors better understand evidence-based medical content in OpenEvidence.”“Clinical research published in peer-reviewed academic journals is the basis of medical science, but physicians spend countless hours sifting through volumes of information,” said Dr. Antonio Jorge Forte, MD, Director of MayoExpert, Mayo Clinic. “With OpenEvidence delivering multimedia and information harvested from the leading clinical journal, clinicians can spend less time searching for and gathering information and they can spend more time with their patients.”About OpenEvidenceOpenEvidence’s mission is to organize and expand the world’s collective medical knowledge. OpenEvidence’s first product, its eponymous medical search engine, is now used by hundreds of thousands of logged-in, verified doctors at 10,000+ care centers across the United States. Launched in 2023, OpenEvidence became the fastest platform in the history of the medical industry to surpass 100,000 verified doctor users in the United States. As of this writing, more than 25,000 verified U.S. doctors are registering for OpenEvidence each month. Aside from the iPhone, there has never been a piece of technology adopted by doctors as quickly as OpenEvidence.← See all announcements --- NCCN and OpenEvidence Collaborate to Bring Clinical Oncology Guidelines to Medical AINovember 5, 2025PLYMOUTH MEETING, PA, and MIAMI, FL — Nov 5, 2025 — The National Comprehensive Cancer Network® (NCCN®) and OpenEvidence, the leading AI-powered medical search and decision-support platform, today announced a licensing agreement to make NCCN’s trusted, evidence-based oncology guidelines accessible through OpenEvidence’s medical artificial intelligence technology.Through this licensing agreement, OpenEvidence will integrate content from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and related content from JNCCN—Journal of the National Comprehensive Cancer Network into its clinician-facing AI platform. “NCCN works to advance quality, effective, equitable and accessible cancer care and prevention so that all people can live better lives,” said Crystal S. Denlinger, MD, FACP, Chief Executive Officer of NCCN. “Health information technology organizations like OpenEvidence can play a key role in connecting providers with leading evidence- and expert consensus-based recommendations on cancer care and prevention. This collaboration will help clinicians access trusted recommendations in a way that harnesses the evolving power of artificial intelligence to support learning and care delivery in cancer, grounded in source documentation and references.”This collaboration will enable healthcare professionals, including the hundreds of thousands of U.S. physicians now using OpenEvidence daily, to access NCCN’s evidence-based, expert consensus-driven recommendations via natural-language search. This will allow clinicians to find the best information faster, with context and clarity, while maintaining NCCN’s rigorous standards for accuracy and quality. “NCCN guidelines are the gold standard for oncology practice around the world,” said Daniel Nadler, PhD, CEO of OpenEvidence. “We are honored to work hand-in-hand with NCCN to make this information more accessible in real time, across every clinical setting, through a secure and responsible application of AI. This collaboration represents a major leap toward making expert medical knowledge universally available and actionable.”The collaboration reflects a shared commitment to clinical excellence, transparency, and continuous quality assurance. All NCCN content surfaced on OpenEvidence strictly adheres to NCCN’s established QA review and links to the source document for additional information. This will ensure fidelity to NCCN recommendations while OpenEvidence’s secure and proprietary systems provide additional medical evidence.Through this collaboration, NCCN and OpenEvidence aim to expand how guideline-based knowledge reaches clinicians—combining NCCN’s unparalleled expertise in cancer care with OpenEvidence’s innovative AI technology to empower clinicians, streamline decision-making, and ultimately improve outcomes for patients worldwide.About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. Visit NCCN.org for more information on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other initiatives.About OpenEvidenceOpenEvidence is the fastest-growing clinical decision support platform in the United States, and the most widely used medical search engine among U.S. clinicians. OpenEvidence is trusted by hundreds of thousands of verified healthcare professionals to make high-stakes clinical decisions at the point of care that are sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand global medical knowledge, OpenEvidence is actively used daily, on average, by over 40% of physicians in the United States, spanning more than 10,000 hospitals and medical centers nationwide.← See all announcements